Duke Cancer Institute: Enzalutamide Shows Survival Benefit in Men With Metastatic Prostate Cancer
July 29, 2019
July 29, 2019
DURHAM, North Carolina, July 29 -- Duke Cancer Institute issued the following news release:
A combination of enzalutamide and androgen deprivation therapy (ADT) significantly reduced the risk of metastatic progression or death over time in men with advanced prostate cancer, according to the results of clinical trial led by Duke Cancer Institute.
The findings, published in the Journal of Clinical Oncology, were the product of a multi-institutional study called ARCHES, wh . . .
A combination of enzalutamide and androgen deprivation therapy (ADT) significantly reduced the risk of metastatic progression or death over time in men with advanced prostate cancer, according to the results of clinical trial led by Duke Cancer Institute.
The findings, published in the Journal of Clinical Oncology, were the product of a multi-institutional study called ARCHES, wh . . .